Pharma's Medical Liaisons: From KOLs To Outcomes And Virtual Options
Executive Summary
Compliance issues, boundaries of off-label discussions and an enhanced emphasis on patient health outcomes are shaping how medical science liaisons (MSLs) engage with existing and emerging stakeholders. Scrip spoke to senior executives from UCB, GlaxoSmithKline, Novartis and Indegene, a healthcare solutions provider, among others, on the evolving role of MSLs and the potential value of hybrid models in this environment.
You may also be interested in...
Bayer Execs On Digital Acceleration, Getting The Building Blocks Right
Senior executives from Bayer outlined at a recent summit the contours of digital transformation already underway and the vital components of a successful digital team. Firms need to be able to operate technology at the “speed of business” and not “at the speed of a ticketing queue.”
Off-Label Communication Principles From PhRMA, BIO Aim For Reg Changes
Manufacturer communications with providers and payers could include real-world evidence and pharmacoeconomic information, associations urge.
Consumer-Focused Off-Label Promotion Seems Possible After Amarin Settlement
Legal agreement with FDA allowing communication about off-label Vascepa use is not limited by audience, speaker or setting, attorneys say.